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Abstract
Introduction:  The objective  of  this  study was  to  evaluate  the  effect  of  selenium
supplementation on autoantibody titres, thyroid ultrasonography, and thyroid function
in patients with Hashimoto's thyroiditis (autoimmune thyroiditis) and normal thyroid
reference range. 
Material and methods: A total of 100 patients were given 200 ug/d selenium yeast
orally, their thyroid function, levels of serum selenium, thyroid peroxidase antibodies
(TPOAb),  thyroglobulin  antibodies  (TGAb),  and urine iodine  were measured,  and
thyroid  ultrasonography  was  performed  before  administration  and  three  and  six
months afterwards, and the data were statistically analysed. 
Results:  The subjects exhibited a selenium deficiency before the administration of
selenium, and the serum levels increased to moderate levels three and six months after
the selenium supplementation (p < 0.05). The titres of TGAb decreased significantly
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in  patients  after  six  months  of  selenium supplementation  (p < 0.05).  In  the  high
antibody group, TgAb decreased after 6 months compared with baseline (p = p <
0.05),  and  TPOAb decreased  after  3  and  6  months  of  selenium supplementation
compared with baseline (p < 0.05). 
Conclusion:  In patients with autoimmune thyroiditis and normal thyroid reference
range, there was a general selenium deficiency, but after six months of treatment it
was shown that selenium supplementation may be effective in reducing the titres of
TGAb and TPOAb. 
Key words: selenium yeast; Hashimoto’s thyroiditis; thyroglobulin antibody; thyroid
peroxidase antibody
Introduction
Due  to  the  increasing  prevalence  of  Hashimoto's  thyroiditis  [1–3],  research
concerning its prevention and control has been intensified. The results of different
studies regarding the therapeutic effect of selenium supplementation on autoimmune
thyroiditis have so far been inconsistent [4–5].
Material and methods 
A total of 100 patients with autoimmune thyroiditis at the Endocrine Centre of
Beijing  Luhe  Hospital  affiliated  to  the  Capital  Medical  University,  who  met  the
inclusion criteria, were enrolled in the study between August 2017 and October 2018.
The patients were given 200 ug/d selenium yeast orally, and their thyroid function,
levels  of  serum  selenium,  thyroid  peroxidase  antibodies  (TPOAb),  thyroglobulin
antibodies (TGAb), and urine iodine were measured and thyroid ultrasonography was
performed before administration and three and six months afterwards, and the data
were statistically analysed. 
All the data were input into an Excel spreadsheet and imported into the SPSS
22.0  software  for  statistical  analysis.  The  countable  data  were  expressed  as
frequencies, and an χ2 test was used to compare the groups while measurement data
with a normal distribution were expressed as x ± s, and a paired samples t-test was
used  for  the  comparison.  The  non-normally  distributed  measurement  data  were
expressed as medians (quartiles) (M [Q1, Q3]), and the Wilcoxon rank-sum test was




The average initial serum selenium level was 72.93 ± 43.242 ng/mL, and the
patients were in a selenium-deficient nutritional state, while the average initial urine
iodine level was 110.80 ug/L, which indicated that the patients were in an iodine-
adequate nutritional state. After three and six months of selenium supplementation
therapy, the overall serum selenium level in patients increased significantly (p < 0.05),
while the urine iodine level remained relatively stable without any significant change
(p > 0.05 in all) (Tab. 1).
The  overall  levels  of  TGAb  were  lower  after  three  months  of  selenium
supplementation therapy, but the difference was not statistically significant (p > 0.05).
After six months of selenium supplementation therapy, the overall levels of thyroid
autoantibodies continued to decrease (p < 0.05). For TPOAB, after 3 and 6 months of
selenium  supplementation,  although  there  was  a  downward  trend  compared  with
baseline, there was no statistically significant difference (p ≥ 0.05). 
On this  basis,  further  stratified analysis  was conducted.  The baseline  median
antibody of all patients was taken as the cut-off point (TgAb 296.30U/mL, TpoAb
204.70 U/mL), and patients with either of the two antibodies higher than this cut-off
point were divided into the high antibody group (TgAb > 300 U/mL or TpoAb > 200
U/mL). Patients with both antibodies below this cut-off point were divided into the
low antibody group  (TgAb <  300  U/mL and TpoAb <  200 U/mL).  In  the  high-
antibody  group,  TgAb decreased  at  6  months  from baseline  (p  <  0.05),  but  this
difference was not significant at 3 months (p > 0.05). TPOAb decreased at 3 and 6
months after Se supplementation compared with baseline (both p <0.05). In the low
antibody group, TgAb and TpoAb did not change significantly from baseline at either
three or six months after Se supplementation (p > 0.05) (Tab. 2).
Effectiveness analysis was conducted for different groups of patients. A total of
100 patients were included in this study, with a loss of follow-up rate of 11%, and 89
patients remained at the end of the study. There were 49 patients in the high antibody
group and 40 patients in the low antibody group. In the above groups, the effective
rate  of  patients  in  the  high  antibody  group  after  supplementing  selenium  was
significantly higher than that of the other two groups (Tab. 3).
Discussion
4
At present, it may be related to insufficient sample size. Further stratified analysis
showed that in patients with high antibody levels (TgAb > 300 or TpoAb > 200),
TpoAb antibodies  decreased  after  three  months  of  selenium supplementation,  and
both  TpoAb  and  TgAb  decreased  after  six  months  of  selenium supplementation.
However, no such effect was observed in the low antibody group. Since the antibody
level reflects the activity of inflammation to some extent, this may be one of the main
reasons for the better effect of selenium supplementation in people with high antibody
levels, but this needs to be further confirmed by further studies. In summary, selenium
supplementation  could  be  beneficial  in  the  specific  patient  population  with
autoimmune thyroiditis described above. 
Because the overall thyroid function in those patients remained relatively stable,
the possibility that selenium supplementation might have a protective effect on the
thyroid gland and stabilise thyroid function could not be excluded, and this needs to
be verified in further studies.
Conclusions
Prevention of selenium deficiency may benefit some patients with autoimmune
thyroiditis. However, before making the decision to supplement selenium, it would be
advisable to  adequately assess the overall status of the patient in order to obtain the
most suitable intervention. 
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Table 1. The changes in thyroid function and the results of thyroid ultrasonography









0.082 1.10  ±
0.198
0.443




0.327 7.30  ±
1.69
0.358




0.097 2.97  ±
0.361
0.540





















Diffuse gridded changes with 10 15 16
6
a solitary thyroid nodule
Diffuse gridded changes with
multiple thyroid nodules
18 17 20
T3 — triiodothyronine; T4 — thyroxine; FT3 — free triiodothyronine; FT4 — free thyroxine;
TSH — thyroid-stimulating hormone
Table 2. The changes in selenium, iodine, and thyroid autoantibodies 
Groups  (n  =
89)


















































396 (278, 476) 278  (182,
436)















72.9 ± 43.2 132 ± 52.8 <
0.001









0.185 127  (82.8,
238)
0.736 0.558
p  <  0.05  indicated  a  significant  difference;  high  antibody group  —  patients  with  either
antibody above  the  baseline  population  median,  i.e.  TgAb >  300  or  TpoAb  >  200; low
antibody group — both antibodies were lower than the baseline population median in the
slow-response population, i.e. thyroglobulin antibodies (TGAb) < 300 and thyroid peroxidase
antibodies (TPOAb) < 200; p1 — comparison between results after 3 months and results of
baseline; p2 — comparison between results after 6 months and results of baseline; P3 —
comparison between results after 6 months and results after 3 months
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Table  3. Effectiveness  analysis  of  selenium supplementation  in  the  same  patient
population
After 3 months After 6 months
TGAb↓ TPOAb↓ TGAb↓ TPOAb↓
n (%) n (%) n (%) n (%)
Total  (n
= 89)










12 30.00 9 22.50 14 35.00 13 32.50
The  decrease  of  antibody  is  compared  to  the  baseline  level;  TGAb  —  thyroglobulin
antibodies; TPOAb — thyroid peroxidase antibodies
